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Summary In hepatocellular carcinoma, mutation within the p53 gene occurs mainly at codon 249 and its
frequency has been associated with exposure to aflatoxin. As Senegal is a country where liver cancer incidence
is one of the highest in the world and where people are highly exposed to aflatoxin, we screened 15 liver cancer
samples from this country for mutation at codon 249 of the p53 gene.
Non-tumoral DNA from the patients showed a wild type genotype. Mutation at codon 249 of the p53 gene
was detected in 10 of the 15 tumour tissues tested (67%). This frequency of mutation in codon 249 of the p53
gene is the highest described. These results confirmed that there is an association between countries of high
aflatoxin intake and a high frequency of mutation in codon 249 of p53 gene, and that HBV alone does not
contribute to these base changes.
Most cancers have p53 gene mutations. However both sites,
and types of mutations, differ among cancers of different
tissue origin (Hollstein et al., 1991). In hepatocellular car-
cinoma (HCC) mutation within the p53 gene occurs mainly
at codon 249 (Bressac et al., 1991, Hsu et al., 1991).
Hepatocellular carcinoma is one of the most frequently
occurring cancers worldwide and high incidence areas are
South-East Asia and sub-Saharan Africa. In these countries,
hepatitis B virus infection and exposure to aflatoxin are the
two major risk factors (Munoz & Bosch, 1987). It has been
suggested that aflatoxin B 1 is responsible for mutation
observed in codon 249 of the p53 gene (Bressac et al., 1991;
Hsu et al., 1991; Hayward et al., 1991). Accordingly, the
frequency of this mutation vary greatly depending on the
country of origin of cancer patients (Bressac et al., 1991;
Hayward et al., 1991; Ozturk et al., 1991), and it has been
linked to the degree of exposure to aflatoxin (Ozturk et al.,
1991). Point mutation in codon 249 of the p53 gene results in
the abolition of a restriction site for the enzyme Hae III
(Bressac et al., 1991). Thus mutation screening could be
performed, combining the polymerase chain reaction (PCR)
with restriction analysis of the amplified DNA sequence.
As Senegal is a country where HCC incidence is one of the
highest in the world (Diop et al., 1981) and where people are
highly exposed to aflatoxin (Wild et al., 1990), we screened
15 HCC DNA samples from this country for mutation at
codon 249 of the p53 gene.
Materials and methods
Frozen liver specimens obtained at necropsy were collected
from 15 Senegalese patients suffering from liver cancer. Tis-
sues were frozen immediately after necropsy and stored at
- 20°C until analysis. DNA was extracted from the liver by
Dyke's procedure (1988) with minor modifications. Briefly,
50 to 100mg of tumoral and non-tumoral tissue sections
from the same patients were minced in 1 ml of PBS and
incubated at 55°C for 2 h with 1 ml of a lysis solution which
contained 0.4 M NaCl, 4 mM EDTA (pH 8), 3% SDS and
2.5 mg ml' proteinase K (Boehringer Mannheim). Proteins
were precipitated by addition of NaCl (at a final concentra-
tion of 1 M), shaking vigorously, followed by centrifugation
at 2500 rpm for 15 min. Total DNA was precipitated over-
night (- 20°C) with ethanol and redissolved in 50 ,sl of
10 mM tris-HCI (pH 7.5), 1 mM EDTA.
HBV DNA analysis
Selected oligonucleotide primers (Thiers et al., 1988) were
synthesised using a DNA synthesiser apparatus (Gene
assembler plus, Pharmacia). The primers 5'-CATCTTCTT-
GTTGGTTCTTCTG-3' (Position 429-450) and 5'-TTAGG-
GTTTAAATGTATACCC-3' (Position 824-844) are located
in the S gene region of HBV. The reaction mixture contained
2 units of Taq polymerase (Promega), 50 pM of each primer,
200 tM of each dNTP and S pil of extracted DNA. The
samples were subjected to 35 cycles of amplification including
denaturation at 94'C for 30 s, annealing of primers at 50°C
for 30 s, and elongation at 75°C for 1 min. The amplified
products were run through 1.6% agarose gels and stained
with ethidium-bromide.
p53 gene analysis
DNA extracted from the various tumoral and non-tumoral
tissue sections of the liver from 15 Senegalese patients were
used. The PCR procedure consisted of 35 cycles of 94°C
(30 s), 60°C (30 s), and 75°C (1 min). The primers used: 5'-
GTTGGCTCGACTGTACCAC-3' and 5'-CTGGAGTCT-
TCCAGTGTGAT-3' were two of those described by Bressac
B et al. (1991).
After purification and concentration on a centrifugal-
driven ultrafiltration membrane (Ultrafree-MC filter unit,
Millipore), PCR products were then restricted to 3 h 30 min
at 37°C with 10 U, Hae III (Pharmacia) in a final volume of
10 sl. The resulting digests were run through 5% NuSieve°
3/1 agarose (FMC Corporation) gels and stained with
ethidium-bromide.
Hae III digestion resulted in two fragments of 75 bp and
35 bp lengths. In the presence of a mutation in codon 249
only one 110 bp fragment is detected after Hae III digestion.
To verify that conservation of the 110 bp fragment after
Hae III digestion was not due to the presence of inhibitors of
the enzyme in the tumour tissue, two amplified P53 samples
were sequenced by Sanger's method using Vent DNA
polymerase (Biolab) (Sears et al., 1992) and 33PdATP (Zagur-
sky et al., 1991). The same set of sense and antisense primers
utilised for DNA amplification by PCR were used as
sequencing primers.
Results
The presence of HBV DNA (Figure 1, Table I) was detected
by PCR in 13 (87%) of the patients. DNA extracted from
non tumoral liver tissue from ten of the patients showed a
non-mutated p53 genotype. Mutation at codon 249 of the
p53 gene (Figure 2, Table I) was detected in ten of the 15
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Figure 1 Detection of HBV DNA by PCR in liver tissue from
HCC patients. Lanes 2-6 show bands at 417 base pairs. Lane 7:
negative control. Lane I and 8 marker fragments generated by
Bgl 1 and Hinf I cleavage of phage pBR 328 DNA.




Figure 2 Detection of mutation at codon 249 of the p53 gene by
digestion of specific amplified sequences with Hae III. Lane 2
shows the p53 amplified sequence ( 10 bp) before restriction, lane
4 and 7 show bands at 35 and 75 base pairs indicating total
cleavage of the original 110 base pair fragment, lane 3 and 6
show the mutated p53 gene, and lane 5 show presence of both
wild type and mutated P53 gene. Lane 1 and 8 marker fragments
generated by Hae III cleavage of phage (X 174 DNA.
tumours tested (67%). The mutation was observed in eight
out 13(62%) of HBV DNA positive patients and in the two
patients without evidence of HBV infection. Seven out of the
ten tumours with codon 249 mutation also had wild-type 249
sequences (Figure 2). This could be due either to the presence
of both mutant and wild type p53 gene alleles in the tumours
or to the presence normal hepatocytes and/or blood cells in
the samples tested. Amplified DNA from two mutated sam-
ples were sequenced and mutation AGG to AGT was
observed at codon 249 in both.
Discussion
The frequency of mutation within codon 249 of the p53 gene
observed in Senegal (67%) is the highest reported to date and
is higher than that observed by Ozturk et al. (1991) in
Mozambique (53%) and by Hsu et al. (1991) in China
Table I HBV-DNA and P53 mutation detection in HCC
patients
P53 mutation in codon 249
Case No HBV-DNA Normal tissue HCC tissue
I + ND +
2 + - +
3 + ND +
4 + - +
5 + - +
6 + _
7 + _ _
8 + ND +
9 - - +
10 - ND +
11 + - +
12 + - +
13 + ND -
14 + - -
15 + -
ND = not done.
(50%). It must be noted that in Asian countries with high
economic standards and low levels of aflatoxin intake, such
as Japan, Taiwan and South Korea, mutation at codon 249
has not been observed (Ozturk et al., 1991; Murakami et al.,
1991; Hosono et al., 1991), in contrast to regions with high
aflatoxin intake like the Qidong province of China or Viet-
nam (Hsu et al., 1991; Ozturk et al., 1991). In Africa, where
aflatoxin intake is very high, the two countries tested had a
high frequency of P53 mutation at codon 249. The results
obtained in Senegal confirm the association between high
aflatoxin intake and high frequency ofmutation in codon 249
of p53 gene in hepatocellular carcinomas.
Fujimoto et al. (1992) did not find this P53 mutation in
four non-human primates having aflatoxin B1 induced
primary hepatocellular carcinoma, and suggested that
hepatitis B virus could be a prerequisite for aflatoxin to
induce this mutation. In this study, we observed two human
cases without evidence of current HBV replication but with
P53 mutation at codon 249. However, all HBsAg negative
liver cancer patients from Senegal we have tested (Coursaget
et al., 1985), have evidence of past HBV infection.
Factors associated with chronic inflammatory and hepatic
regeneration changes induced by hepatitis B virus, have been
found to be important risk factors for hepatocarcinogenesis.
In addition, loss of normal p53 function due to mutations
may be a key step during malignant transformation of
hepatocytes. Harris (1991) suggested that the interaction of a
virally encoded protein with the specific mutant p53 provides
a growth advantage in hepatomas. This hypothesis has been
confirmed by Sell et al. (1991) since hepatitis B virus acts
synergistically with aflatoxin in transgenic mice to produce
neoplasia of the liver.
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